共 110 条
[1]
Silver DA(1997)Prostate-specific membrane antigen expression in normal and malignant human tissues Clin Cancer Res: Off J Am Assoc Cancer Res 3 81-5
[2]
Pellicer I(2014)Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises J Biol Regul Homeost Agents 28 555-63
[3]
Fair WR(2007)Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique Histopathology 50 472-83
[4]
Heston WD(2004)Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 528-39
[5]
Cordon-Cardo C(2007)Targeted treatment of prostate cancer J Cell Biochem 102 571-9
[6]
Santoni M(2013)Synthesis of peptide radiopharmaceuticals for the therapy and diagnosis of tumor diseases Molecules 18 3379-409
[7]
Scarpelli M(2015)Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer J Nucl Med: Off Publ Soc Nucl Med 56 914-20
[8]
Mazzucchelli R(2015)The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions J Nucl Med: Off Publ Soc Nucl Med 56 1697-705
[9]
Lopez-Beltran A(2016)Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer Oncotarget 7 12477-88
[10]
Cheng L(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-8